Author Affiliations: Department of Cardiology, Mayo Clinic and Foundation, Rochester, Minn (Dr Pislaru) and Department of Cardiology, Gasthuisberg University Hospital and University of Leuven, Leuven, Belgium (Dr Van de Werf).
The possible association between Chlamydia pneumoniae and atherosclerosis was first reported in 1988 by Saikku et al1 who noted that antichlamydial antibodies were present
more often among patients with acute myocardial infarction (MI) than among
matched controls. Since then, several other serological studies have yielded
conflicting results about this association, possibly due to lack of uniformity
in methods used (ie, different classes of antibodies tested, different methods,
different cutoff points) and by the high prevalence of C pneumoniae exposure in the population. On the other hand, data from
basic laboratory studies have strongly suggested a possible role of C pneumoniae in the etiology of atherosclerosis. Cells
involved in atherogenesis (vascular endothelial cells, smooth muscle cells,
macrophages, and platelets) have been found to be infected by C pneumoniae.2 In mouse and rabbit models, C pneumoniae has been detected in the vasculature after
nasal inoculation and has been associated with various degrees of atherogenesis
pneumoniae also has been documented in atherosclerotic lesions from
Pislaru SV, Van de Werf F. Antibiotic Therapy for Coronary Artery Disease: Can a WIZARD Change It All? JAMA. 2003;290(11):1515–1516. doi:10.1001/jama.290.11.1515
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: